New drug duo aims to keep leukemia in check longer

NCT ID NCT05057494

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 600 participants will receive either acalabrutinib plus venetoclax or venetoclax plus obinutuzumab. The goal is to see which combination controls the cancer longer and leaves fewer cancer cells behind.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Research Site

Tucson, Arizona, 85710, United States
Research Site

La Jolla, California, 92093-0052, United States
Research Site

Longmont, Colorado, 80501, United States
Research Site

Jacksonville, Florida, 32256, United States
Research Site

Boston, Massachusetts, 02115, United States
Research Site

Rochester, Minnesota, 55905, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

Buffalo, New York, 14263, United States
Research Site

New Hyde Park, New York, 11040, United States
Research Site

New York, New York, 10065, United States
Research Site

Rochester, New York, 14642, United States
Research Site

Charlotte, North Carolina, 28204, United States
Research Site

Cleveland, Ohio, 44195, United States
Research Site

Eugene, Oregon, 97401, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Charlottesville, Virginia, 22908, United States
Research Site

Seattle, Washington, 98104, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Clayton, 3168, Australia
Research Site

Nedlands, 6009, Australia
Research Site

Waratah, 2298, Australia
Research Site

Hradec Králové, 500 05, Czechia
Research Site

Ostrava - Poruba, 708 52, Czechia
Research Site

Pilsen, 30460, CZ, Czechia
Research Site

Montpellier, 34295, France
Research Site

Tours, 37044, France
Research Site

Budapest, 1097, Hungary
Research Site

Debrecen, 4032, Hungary
Research Site

Bydgoszcz, 85-168, Poland
Research Site

Gdansk, 80-219, Poland
Research Site

Katowice, 40-519, Poland
Research Site

Krakow, 30-727, Poland
Research Site

Lódz, 93-513, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Barcelona, 08025, Spain
Research Site

Palma de Mallorca, 07010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.